In line with lead optimization processes, we here report the development of the novel PDE4D full inhibitor GEBR-32a, a compound that exhibits improved brain and cell penetration and that is able to efficiently increase cAMP levels, to rescue impaired hippocampal LTP and to improve memory function in normal and AD mice. Here, PDE4D is linked to Alzheimer disease.